
FDA Adds Warning to Osteoporosis Drug for Hypocalcemia Risk
The FDA has updated the label of the osteoporosis drug denosumab to include a boxed warning about increased risk for severe hypocalcemia in patients with advanced chronic kidney disease (CKD). This new warning is based on evidence indicating a significant risk for hypocalcemia in patients with CKD-MBD. Healthcare professionals are advised to assess patients’ kidney…